Having trouble viewing this email? View in your browser.
ESCMID Logo

17 January 2017
WEEKLY NEWS

Dear colleagues,

Check out our preliminary programme for ECCMID from 22 – 25 April 2017 in Vienna, Austria. The early-bird registration deadline will apply until 26 January.

Your ESCMID communications editors

 

ESGBIS publishes study on predictive score for BSI outcome in JAC

Bloodstream infections (BSIs) due to extended-spectrum-beta-lactamase-producing Enterobacteriaceae (ESBL-E) are frequent, but outcome prediction rules for clinical use have not been developed. An international group of researchers supported by ESCMID’s study group for BSIs defined and validated
an easy-to-collect predictive scoring model for all-cause 30-day mortality useful for identifying patients at high and low risk of mortality. The study was published in the Journal of Antimicrobial Chemotherapy.

› Read more
 

CMI highlight: narrow-spectrum beta-lactam monotherapy in pneumonia

Researchers in Sweden assessed the clinical effect of empirical treatment with narrow-spectrum beta-lactam monotherapy (NSBM) versus broad-spectrum beta-lactam monotherapy (BSBM) in non-severe community-acquired pneumonia (CAP). They observed no significant differences in 30-day and 90-day mortality between NSBM and BSBM. Patients who received BSBM were more often treated in an intensive care unit and had longer length of stay. Empirical NSBM appears to be effective in the majority of hospitalized immunocompetent adults with non-severe CAP and should be further evaluated in randomized trials, the authors concluded.

› Read more
 

ESCMID course on bloodstream infections in Nice

This postgraduate education course from 28 – 31 March targets 20 to 60 microbiologists and infectious disease specialists who want updated knowledge of the theoretical and practical aspects of current and advanced diagnosis and management of bloodstream infection (BSI). Speakers will present advanced technologies to improve disease management in a context of challenges including multi-drug resistant pathogens as well as new approaches including molecular detection tools or biofilm or anti-infective lock therapy in catheter-associated BSI. Find out more about the programme, grant application and registration timelines.

› Read more
ESCMID Executive Office
P.O. Box 214
4010 Basel
Switzerland
Phone +41 61 5080 173
info@escmid.org
www.escmid.org
Follow ESCMID
Visit us on LinkedIn Visit us on YouTube
 
The ESCMID Newsletter is issued on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) by the ESCMID Executive Office. It contains announcements of ESCMID-related matters and other information of interest to professionals in the infection field.

Tip: To ensure that you receive the ESCMID newsletter in your inbox, add newsletter@escmid.org to your email program’s address book.

You have received this email as a contact of ESCMID or one of its affiliated societies. You can unsubscribe or change your newsletter subscriptions here.